Sign In
Buy KYMR
$73.21
+1.92 (+2.69%)
At Close: Jun 03, 2026
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
10:33am, Thursday, 10'th Oct 2024
KYMR will initiate dosing in a phase I study on KT-621, an investigational first-in-class once daily, oral STAT6 degrader, following IND clearance by the FDA.
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
07:00am, Wednesday, 09'th Oct 2024
KT-621 has demonstrated dupilumab-like activity and was well tolerated in a wide variety of preclinical models of TH2 diseases
Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors
02:58pm, Sunday, 06'th Oct 2024
Kymera Therapeutics' innovative TPD technology degrades disease-causing proteins, with promising candidates like KT-474 and KT-621 targeting large TAMs in immunology and oncology. The company's approa
Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress
07:00am, Wednesday, 25'th Sep 2024
KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease
Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?
12:37pm, Friday, 06'th Sep 2024
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock?
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
07:00am, Wednesday, 28'th Aug 2024
WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete
WATERTOWN, Mass., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete
Kymera (KYMR) to Raise $225 Million Through Offering of Shares
02:05pm, Tuesday, 20'th Aug 2024
Kymera (KYMR) is in the process of selling approximately 2 million shares of common stock at a public offering price of $40.75 per share, along with pre-funded warrants to purchase 3,519,159 shares in
Kymera Therapeutics Announces Pricing of $225 Million Public Offering
10:45pm, Monday, 19'th Aug 2024
WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete
Kymera Therapeutics Announces Proposed Public Offering
04:01pm, Monday, 19'th Aug 2024
WATERTOWN, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete
Kymera Therapeutics, Inc. (KYMR) Q2 2024 Earnings Call Transcript
11:23am, Saturday, 10'th Aug 2024
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET Company Participants Justine Koenigsberg - Vice President, Investor Relations Nello Mainolfi - Found
Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus
10:56am, Thursday, 08'th Aug 2024
Kymera (KYMR) reports a narrower-than-expected loss in the second quarter. The company expects the current cash balance to provide a runway into the first half of 2027.
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
09:11am, Wednesday, 07'th Aug 2024
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.67 per share a year ago.
Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7
07:00am, Wednesday, 31'st Jul 2024
Watertown, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete
Kymera Therapeutics: Solid Progress And No Change To My 'Buy' Rating
04:58am, Tuesday, 16'th Jul 2024
Kymera Therapeutics is a protein degradation specialist drug developer with promising Phase 1 and 2 stage protein degraders targeting various diseases. A partnership with Sanofi includes potential mil
